Posted by Michael Wonder on 22 Jun 2022
FDA grants breakthrough device designation to VR mental illness treatment
22 June 2022 - A British startup that uses virtual reality to help deliver cognitive behaviour therapy has been granted a breakthrough device designation by the FDA for its treatment for schizophrenia and other serious mental illnesses, a process that will help expedite its ultimate approval if clinical trials pan out.
The treatment from OxfordVR uses virtual reality headsets to guide patients through everyday situations like going to a store, riding a bus, or visiting a doctor’s office which can cause fear and anxiety for those suffering from psychosis.
